Health

Limited Options for COVID-19 Vaccine Injury Victims

Published

4 years ago

August 13, 2022

Rolling out vaccines and booster shots across the U.S. marked crucial milestones in terms of healthcare and fighting the spread of COVID-19. However, an essential element is still missing: legal recourse for those who experience serious adverse side effects.

Current COVID-19 Vaccine Injury Claims

Currently, there are more than 1,300 pending injury claims related to side effects from the COVID-19 vaccine. They are waiting to be heard by the Vaccine Injury Compensation Program, a government tribunal that handles public health emergencies.

To date, this tribunal has only handled two such cases. One alleged the plaintiff suffered from severe tongue and throat swelling following the vaccine, while the other alleged long-term shoulder pain. Plaintiffs lost both cases and were denied compensation.

Given the comparatively new nature of the COVID-19 vaccine, it is challenging for plaintiffs to prove that their injuries directly resulted from the vaccine. Combined with the lack of research on long-term side effects, it is unlikely that plaintiffs will be able to meet this burden of proof anytime in the near future.

How COVID-19 Vaccine Injury Claims Are Handled

Of interest is that claims related to the COVID-19 vaccine are being heard by the Countermeasures Injury Compensation Program (CICP) instead of the Vaccine Injury Compensation Program, a no-fault government tribunal; known colloquially as “vaccine court.”

Formed in the late 1980s, the Vaccine Injury Compensation Program responded to diphtheria, pertussis, and tetanus (DPT) vaccine claims. Pharmaceutical companies were listed as defendants in lawsuits related to vaccine side effects. However, the government created a separate entity to handle such cases when manufacturers threatened to stop producing vaccines altogether.

The Centers for Disease Control and Prevention (CDC) clarified that the Vaccine Injury Compensation Program could not hear cases until the COVID-19 vaccine has been recommended for routine administration to children, per a 1986 vaccine law. Additionally, the COVID-19 vaccine would have to be subject to the same 75-cent tax imposed on other vaccines.

Compensation From the CICP

There are several differences between the two tribunals, which plaintiffs claim make the CICP inappropriate for COVID-19 vaccine injury litigation. Of these, compensation is one of the biggest causes for concern.

The Vaccine Injury Compensation Program has awarded injured plaintiffs more than $4 billion since its inception. In comparison, the CICP has only awarded compensation for 29 of 455 cases— that means that 92 percent of plaintiffs are deemed ineligible or denied compensation. Compensation ranged from $31 to nearly $2.3 million, with a median award of roughly $5,600.

This is partly because compensation options from the CICP are much more limited. Plaintiffs can only claim lost wages and out-of-pocket medical expenses up to $50,000 per year or death benefits up to $370,376 in the case of a vaccine-related fatality.

Differences Between Vaccine Injury Compensation Programs

Below are other key differences between the Vaccine Injury Compensation Program and the Countermeasures Injury Compensation Program:

Plaintiffs do not have the opportunity to testify in court
There is no independent judge or jury present
Pain and suffering-related damages are not covered
There is a limited right to appeal one’s case

This means that plaintiffs who file a case related to injuries allegedly caused by the COVID-19 vaccine are offered less compensation, less legal representation, and less recourse through appeals as opposed to plaintiffs who file a case for injuries caused by any other vaccine. Still, if you are experiencing symptoms related to the COVID-19 vaccine, it may be in your best interest to speak with an injury attorney.

Health

BioLongevity Labs: How Two Biohackers Are Making Longevity Safe for the Mainstream

Published

4 hours ago

February 18, 2026

Michelle Langton

Humans have been looking for ways to extend their lifespan for hundreds of years. Medicine has made impressive strides, but for many, the effects of aging are still painfully real.

Through BioLongevity Labs, biohackers and entrepreneurs Jay Campbell and Josh Felber aim to introduce ordinary people to potentially life-changing compounds called peptides. Campbell and Felber come from very different backgrounds.

Campbell is a five-time international bestselling author and globally recognized leader in the health-optimization space. Felber is a serial entrepreneur who excels at scaling businesses.

For both men, BioLongevity Labs is more than just a business venture — it’s about helping everyday people discover something that just might prolong and improve their lives.

“Your body inevitably changes as the years pile on,” says Campbell. “Your energy drops, and wrinkles start showing up uninvited. Peptides can change everything.”

Many people have probably heard the term “peptide” in passing. Some may know they’re associated with longevity. Most people just don’t have a strong grasp of how they work.

A peptide is a short chain of amino acids, which are the building blocks of proteins. Essentially, peptides are like shorter, simpler proteins. That might sound unremarkable, but the real magic of peptides lies in how they work.

They function as signaling or “messenger” molecules telling the body to perform specific functions. Many peptides function similarly to hormones. A relevant example is GLP-1 (glucagon-like peptide-1) receptor agonists. This class of medications includes semaglutide and tirzepatide, two wildly popular weight-loss drugs.

“These peptides aren’t just another biohacking fad,” Campbell explains. “They enhance insulin secretion and suppress glucagon release to balance blood sugar levels and promote sustainable weight loss”. But what sets GLP-1 receptor agonists apart is their ability to regulate hunger.

Through the reduction of appetite and increased feelings of fullness, it is far easier for dieters to stick to a calorie deficit.” Although GLP-1 receptor agonists are widely prescribed, most peptides aren’t.

Campbell asserts, because many peptides have the potential to cure illnesses by treating the fundamental root cause, they go against America’s “sick care” model of healthcare. They potentially threaten drug companies and their bottom line.

“Peptides are simultaneously a dream come true for mankind and the worst possible nightmare for the pharmaceutical industry,” says Campbell. “It’s not a conspiracy theory. It’s pure economics and psychology in action. People will do whatever it takes to make as much money as possible in a free-market society, even if it means suppressing a superior solution.”

Patients probably aren’t going to be introduced to peptides through the healthcare system. Many discover them on their own. But for the many people who don’t have a solid understanding of how they work molecularly or even what dose to take, there is a risk. That’s precisely what BioLongevity Labs’ co-founders are attempting to address.

Jay Campbell has dedicated his life to educating people about therapeutic peptides and optimized hormones, and along with his partner Josh Felber, they’ve created a company offering filler-free, third-party tested peptides and bioregulators.

Campbell and Felber stress the fact that BioLongevity Labs isn’t meant to be a replacement for traditional medical care. Instead, its products bridge the gap between clinical and extra-clinical care. There’s no magic pill or single solution to solve the problem of aging.

But thanks to the development of specialized peptides, bioregulators, and small molecules, we’re closer than we’ve ever been before.